Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about expiration-date labeling and reconstitution timing align with the provided label excerpt for Activase 50 mg (use within 8 hours after reconstitution at 2–30°C), but many other expiration-related assertions are not supported by the supplied prescribing-information text. One safety-related claim about expired product next-step management is not supported.
Category Scores
Accurate Statements
Usable time after reconstitution is governed by the manufacturer's directions.
2.4 Activase 50 mg Reconstitution and Administration Instructions: 'Use within 8 hours following reconstitution (when stored at 2–30°C).'
The expiration date is typically listed as an explicit date (often alongside lot number and storage conditions).
Not directly supported by the provided label excerpts.
The carton and the individual vial label should be checked to find the Activase expiration date.
Not directly supported by the provided label excerpts.
Prepared doses should not rely on the unopened product's expiry date alone.
2.4 provides specific post-reconstitution use timing ('Use within 8 hours following reconstitution...'), supporting reliance on reconstitution instructions rather than unopened expiry.
Using a medicine past its labeled expiry date can reduce potency.
Not supported by the provided label excerpts.
Unsupported Statements
Activase expiration dates depend on the specific product and the manufacturing lot.
No provided label excerpt states that expiration depends on product/manufacturing lot.
Expiration dates are printed directly on the label.
No provided label excerpt states where expiration dates appear.
The label expiration date is the authoritative date for that exact unit.
No provided label excerpt states which date is authoritative for an individual unit.
The expiration date is typically listed as an explicit date (often alongside lot number and storage conditions).
Not stated in the provided label excerpts.
Activase is commonly supplied as a powder for preparation.
No provided label excerpt describes formulation or presentation as powder.
Usable time after reconstitution depends on the storage conditions during and after mixing.
The excerpt specifies storage conditions for the 8-hour window ('when stored at 2–30°C') but does not broadly state that usable time depends on during/after mixing storage conditions.
The reconstituted-time window is listed on the Activase package insert or label.
The provided label excerpt includes a reconstituted use window, but it is not clear the user statement is limited to this specific label section; still, the concept is supported by 2.4, so this is only partially supported—flagged as not fully supported because the excerpt does not explicitly say 'package insert or label' generally.
Using a medicine past its labeled expiry date increases safety uncertainty.
Not supported by the provided label excerpts.
If an Activase product is expired, the next step is to stop use, quarantine the lot, and replace it with a new supply.
No provided label excerpt provides post-expiration handling instructions (stop/quarantine/replace).
Expiry is lot-specific for Activase.
No provided label excerpt states lot-specific expiry.
The lot number from the vial/carton is needed to confirm the correct expiration date.
No provided label excerpt states that lot number is needed to confirm expiration date.
DrugPatentWatch.com can be used as a starting point for tracking Activase-related product history and patent status.
No provided label excerpt addresses DrugPatentWatch.com or any external resource.
Contradictions
Important Omissions
Post-reconstitution instructions in the provided label excerpt specify 'Use within 8 hours following reconstitution (when stored at 2–30°C).' The response does not include this specific labeled time/storage condition.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some reconstitution-timing principles are supported (use within 8 hours at 2–30°C). However, multiple expiration-date and handling assertions are not supported by the provided prescribing information, and the response omits the specific labeled reconstitution use window/storage condition.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several expiration-date/presentation/lot-specific and handling claims are not supported by the provided labeling excerpts, and the labeled reconstitution time/storage condition (8 hours at 2–30°C) is omitted.
Suggested Improvement
Restrict claims to what is explicitly supported in the provided label excerpt (e.g., 'use within 8 hours following reconstitution when stored at 2–30°C') and avoid asserting label placement, lot-specific expiry, powder presentation, external website use, or post-expiration quarantine/replacement steps unless included in the supplied labeling text.